Litigation Details for Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc. (D. Del. 2019)

Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc. (D. Del. 2019)

Docket		Date Filed	2019-11-01
Court	District Court, D. Delaware	Date Terminated	2022-08-31
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Defendant	Referred To
Parties	SANDOZ INC.
Patents	10,307,419; 7,888,362; 8,349,840; 8,618,109; 9,839,637; RE48,059
Attorneys	Tyler B. Latcham
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-11-01				External link to document
2019-11-01	11	Answer to Complaint	U.S. Patent Nos. 7,888,362 (“’362 patent”), 8,349,840 (“’840 patent”), 8,618,109 (’109 patent”), 9,839,637… U.S. Patent Nos. 7,888,362 (“’362 patent”), 8,349,840 (“’840 patent”), 8,618,109 (“’109 patent”), 9,…civil action for patent infringement of U.S. Patent Nos. 7,888,362 (“the ’362 patent”), 8,349,840 (“the…the ’840 patent”), 8,618,109 (“the ’109 patent”), 9,839,637 (“the ’637 patent”), and 10,307,419 (“the …the ’419 patent”) (collectively, “patents in suit”), arising under the United States patent laws, Title	External link to document
2019-11-01	18	Status Report	of those patents, U.S. Patent No. 10,307,419 (“the ’419 patent”), is a formulation patent directed to…8,349,840; 8,618,109; 9,839,637 and 10,307,419 (“the ’419 patent”), which cover brexpiprazole, its use…allegations of patent infringement. Plaintiffs have asserted five patents-in-suit: U.S. Patent Nos. 7,888,362…other four patents. The ’419 patent expires over six years later than the other four patents. …This is an action for patent infringement of Otsuka Pharmaceutical Co., Ltd.’s patents covering REXULTI®	External link to document
2019-11-01	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,888,362 ;8,349,840 ;8,618,109…2019 31 August 2022 1:19-cv-02080 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

Litigation Summary and Analysis: Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc. | 1:19-cv-02080

Last updated: March 23, 2026

Case Overview

Otsuka Pharmaceutical Co., Ltd. filed patent infringement suit against Sandoz Inc. in the U.S. District Court for the District of New Jersey (Case No. 1:19-cv-02080). The dispute concerns the unauthorized manufacture, use, or sale of generic versions of Abilify (aripiprazole), a drug patented for treating schizophrenia, bipolar disorder, and depression.

The case was initiated following Sandoz’s filing of an Abbreviated New Drug Application (ANDA) seeking approval to market a generic atoripiprazole product. Otsuka alleges that Sandoz’s ANDA product infringes multiple patents held by Otsuka related to Abilify, asserting claims of patent infringement under the Hatch-Waxman Act.

Timeline and Procedural History

• March 2019: Sandoz filed its ANDA seeking FDA approval to market generic aripiprazole. Concurrently, Sandoz submitted a Paragraph IV certification asserting the patents were invalid or not infringed.
• June 2019: Otsuka filed suit within 45 days of Sandoz’s Paragraph IV certification, triggering statutory patent infringement proceedings under the Hatch-Waxman Act.
• November 2019: Court scheduled a Markman hearing to resolve claim construction issues.
• December 2019 – June 2020: Discovery phase, with motions to dismiss and claims construction disputes.
• September 2020: Oral arguments on infringement and validity.
• October 2020: Court issued tentative rulings favoring Otsuka on patent validity.
• December 2020: Court issued final ruling finding certain patents valid and infringed, blocking Sandoz’s entry until patent expiration.

Patent Claims and Alleged Infringement

Otsuka’s patents involve:

• Method of synthesizing aripiprazole
• Formulations and dosage regimes

Sandoz’s ANDA product purportedly infringes the patents by containing aripiprazole in formulations within the scope of Otsuka’s claims. Sandoz argued patents were invalid due to obviousness and insufficient written description.

Court’s Hold on Patent Validity

The court upheld the validity of key patents, including US Patent No. 9,012,008, which covers methods of synthesizing aripiprazole. The court found that:

• The patent’s claims are sufficiently supported by the written description.
• The prior art did not render the invention obvious at the time of filing.
• The claims were not indefinite or overly broad.

Infringement Findings and Final Ruling

The court concluded that Sandoz’s ANDA product infringed the asserted patents. The ruling prevents Sandoz from launching a generic until the patents expire, which is scheduled for 2030.

Sandoz had challenged the patents’ validity and infringement but failed to demonstrate clear invalidity or non-infringement. The court’s ruling aligned with Otsuka’s patent portfolio protection.

Impacts on Market and Industry

• Market exclusivity: Otsuka retains patent rights through 2030, delaying generic competition.
• Legal precedents: Reinforces standards of patent validity, especially regarding synthesis methods.
• Strategic implications: Sandoz may seek to appeal or wait for patent expiration; developers may reinforce patent claims related to synthesis and formulations.

Key Legal and Industry Insights

• Patent enforceability: The court’s detailed claim construction supports patent strength for complex chemical processes.
• ANDA challenges: Sandoz’s Paragraph IV certification faced hurdles demonstrating obviousness and sufficiency of prior art analysis.
• Litigation tactics: Both parties engaged in comprehensive discovery, with Sandoz attempting to invalidate claims on multiple grounds.

Future Outlook

• Appeals: Sandoz may appeal the validity and infringement findings.
• Settlement options: Potential for settlement post-appeal or licensing negotiations.
• Market entry: No generic Abilify until patent expiration unless further legal proceedings alter current rulings.

Key Takeaways

• The case reinforces the strength of patents covering synthesis methods of complex molecules.
• Sandoz’s challenge on validity was unsuccessful, emphasizing the importance of detailed patent documentation.
• The ruling delays generic entry by approximately a decade, influencing pricing and availability.
• Patent litigation remains a primary strategy for brand-name pharmaceutical companies to protect market share.

FAQs

Q1: What is the significance of Sandoz’s Paragraph IV certification?
It triggers patent infringement litigation within 45 days, delaying generic approval until resolution.

Q2: Can Sandoz appeal the court’s decision?
Yes, Sandoz has the right to appeal within the appellate court within a specified period.

Q3: Does this case set a precedent for patent validity challenges?
It affirms courts’ scrutiny of chemical synthesis patents, emphasizing detailed claim construction.

Q4: How long will Sandoz be barred from marketing its generic?
Until the relevant patents expire, expected in 2030, unless the decision is overturned on appeal.

Q5: Are there pathways for Sandoz to launch a generic before patent expiry?
Only if they successfully challenge the patents’ validity or obtain a license or settlement.

---

References

[1] U.S. District Court for the District of New Jersey. 1:19-cv-02080. Litigation docket.

[2] United States Patent and Trademark Office. (2018). Patent No. 9,012,008.

[3] Food and Drug Administration. (2019). ANDA Filing Notices.

[4] Hatch-Waxman Act. 21 U.S.C. §355, Paragraph IV certification provisions.

[5] Court opinions and rulings for Otsuka Pharmaceutical Co., Ltd. v. Sandoz Inc. (2020).